News
Inventors at the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are seeking a licensee or collaborator for positive allosteric modulators (PAMs) of the A 3 adenosine receptor (A 3AR), a known therapeutic target. These heterocyclic chemical compounds bind to a lipid
A research team, led by Dennis Drayna, Ph.D., chief of the Section on Genetics of Communication Disorders at the National Institute on Deafness and Other Communication Disorders (NIDCD), conducted detailed genetic analyses on 1,300 adults. A genetic variant found only in people of African descent
The National Cancer Institute (NCI), through the NCI Technology Transfer Center (TTC), now offers a term-limited, exclusive Start-Up Evaluation Option License to start-up companies developing early-stage vaccine, therapeutic, device, and certain diagnostic technologies. The previous Start-up Program
Proposal(s) are sought in response to RFP # NIH-OD-OLAO-OA-(PLS)-2019 for Patent-Legal Services. This solicitation is full and open to ALL capable business concerns in the U.S. The North American Industry Classification System (NAICS) code for this acquisition is 541110 - Office of Lawyers. In